Get the Stockscreener App
1.63
1.24%
0.02
After Hours:
1.62
-0.010
-0.61%
Geron Corp stock is traded at $1.63, with a volume of 9.88M.
It is up +1.24% in the last 24 hours and up +13.99% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.61
Open:
$1.64
24h Volume:
9.88M
Relative Volume:
1.04
Market Cap:
$1.04B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-5.0938
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+11.64%
1M Performance:
+13.99%
6M Performance:
+20.74%
1Y Performance:
-41.58%
1-Day Range:
$1.55
$1.6475
1-Week Range:
$1.46
$1.6899
52-Week Range:
$1.04
$2.835
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.63 | 1.03B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - The Manila Times
Geron (NASDAQ:GERN) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Several Insiders Invested In Geron Flagging Positive News - Yahoo Finance
Geron Corporation Projects RYTELO Growth Amidst Revised Price Targets - StocksToTrade
Geron Corp Projects Major Revenue Boost for 2026 - StocksToTrade
Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares - simplywall.st
Geron (NASDAQ:GERN) Trading Up 8.4%Should You Buy? - MarketBeat
TD Cowen Revises Geron’s Price Target Amid RYTELO Expansion Plans - StocksToTrade
Geron Corporation (NASDAQ:GERN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results - Finviz
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Geron Stock: Under-Promise And Over-Deliver Could Be The 2026 Strategy (GERN) - Seeking Alpha
Geron (NASDAQ:GERN) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Geron Corporation (NASDAQ:GERN) Nasdaq Index Clinical-Stage Biotech Profile - Kalkine Media
Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive - Insider Monkey
Geron Corporation (GERN) presents new data at the 67th American Society of Hematology 2025 annual meeting - MSN
HC Wainwright Predicts Geron's Q3 Earnings (NASDAQ:GERN) - MarketBeat
Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth - Finviz
What is HC Wainwright's Forecast for Geron FY2030 Earnings? - MarketBeat
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Geron (NASDAQ:GERN) Stock Price Down 6.6%Here's Why - MarketBeat
Geron forecasts $220-240 million in RYTELO revenue for 2026 - Investing.com
Geron forecasts $220-240 million in RYTELO revenue for 2026 By Investing.com - Investing.com South Africa
Geron (GERN) Outlines Strategic Vision with FY26 Expense Forecas - GuruFocus
Geron (GERN) Forecasts Strong Revenue from RYTELO in 2026 - GuruFocus
Geron shares fall 7.5% premarket after 2026 revenue outlook falls short of estimate - marketscreener.com
Geron Corporation Provides 2026 Financial Guidance - TradingView
Geron Corporation (GERN) Stock Analysis: Exploring a 162.77% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Travel Stocks: What margin trends mean for Geron Corporation stockTrade Performance Summary & Technical Analysis for Trade Confirmation - Bộ Nội Vụ
What valuation multiples suggest for Geron Corporation stockJuly 2025 WrapUp & Reliable Intraday Trade Plans - ulpravda.ru
Will Geron Corporation stock benefit from infrastructure spending2025 Risk Factors & Low Drawdown Investment Ideas - ulpravda.ru
Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral - Finviz
Geron Corporation Enters into Certain First Amendment to Loan Agreement with Biopharma Credit Investments V LP and BPCR Limited Partnership - marketscreener.com
Geron extends loan agreement deadlines for $250 million credit facility - Investing.com
Geron extends loan agreement deadlines for $250 million credit facility By Investing.com - Investing.com UK
Geron Signs Loan Agreement Amendment With BioPharma Credit - TradingView — Track All Markets
Geron Corporation (NASDAQ:GERN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Geron Stock Rallies More Than 60% in a Year: Here's Why - MSN
Geron (NASDAQ:GERN) Trading Up 4.9%Time to Buy? - MarketBeat
Geron Corporation (GERN) restructuring to lower operating expenses as it eyes profitability in 2026 - MSN
How Geron Corporation stock compares to market leadersJuly 2025 Price Swings & Precise Buy Zone Identification - Улправда
Can Geron Corporation (GON) stock expand revenue streamsWeekly Trade Report & Smart Investment Allocation Insights - Улправда
What margin trends mean for Geron Corporation stock2025 Volatility Report & Weekly High Potential Alerts - Улправда
Geron: From Launch Hype To Later-Line Gravity (NASDAQ:GERN) - Seeking Alpha
Geron (NASDAQ:GERN) Shares Down 3.9%What's Next? - MarketBeat
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 - Yahoo Finance
Geron (NASDAQ:GERN) Stock Price Up 5.6%Here's What Happened - MarketBeat
14 Best Multibagger Penny Stocks to Buy Right Now - Insider Monkey
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LAWLIS V BRYAN | Director |
May 09 '25 |
Buy |
1.18 |
13,300 |
15,667 |
13,300 |
| Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):